comparemela.com

Latest Breaking News On - Future royalties - Page 2 : comparemela.com

Investegate |Minerva Neurosciences, Inc Announcements | Minerva Neurosciences, Inc: Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates

Investegate announcements from Minerva Neurosciences, Inc, Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates

Fred ahlholmHelen shikRemy luthringerMinerva neurosciencesExchange commissionExchange commission onShik communicationsDrug administrationMinerva neurosciences incCompany to host live webcastMinerva neurosciences reports third quarterNew drug applicationExecutive chairmanChief executive officerInterest expenseFuture royalties

Minerva Neurosciences, Inc: Minerva Neurosciences Reports Second Quarter 2022 Financial Results and Business Updates

Company Continues to Prepare for Potential Submission of an NDA for Roluperidone in the Third Quarter of 2022WALTHAM, Mass., Aug. 09, 2022(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused

Fred ahlholmHelen shikRemy luthringerMinerva neurosciencesShik communicationsDrug administrationMinerva neurosciences incCompany continues to prepare for potential submissionCompany continuesPotential submissionThird quarterDrug administrationon aprilNew drug applicationon aprilExecutive chairmanChief executive officerWeek open label extension

Investegate |Minerva Neurosciences, Inc Announcements | Minerva Neurosciences, Inc: Minerva Neurosciences Reports Second Quarter 2022 Financial Results and Business Updates

Investegate announcements from Minerva Neurosciences, Inc, Minerva Neurosciences Reports Second Quarter 2022 Financial Results and Business Updates

United kingdomFred ahlholmHelen shikRemy luthringerMinerva neurosciencesExchange commissionExchange commission onShik communicationsDrug administrationMinerva neurosciences incCompany continues to prepare for potential submissionMinerva neurosciences reports second quarterPotential submissionThird quarterNew drug applicationExecutive chairman

Aptevo Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

SEATTLE, WA / ACCESSWIRE / May 12, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics

United statesMiriam weber millerMarvin whiteExchange commissionDevelopment expensesAmerican association for cancer researchAptevo therapeutics incCompany phaseAptevo therapeuticsAmerican associationCancer researchLicense agreementAdministrative expensesMidcap credit agreementFuture royaltiesRoyalty purchase agreement

Minerva Neurosciences, Inc: Minerva Neurosciences Reports First Quarter 2022 Financial Results and Business Updates

Company Expects to Submit an NDA for Roluperidone, Subject to FDA Guidance, in the Third Quarter of 2022WALTHAM, Mass., May 04, 2022 (GLOBE NEWSWIRE) Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage

Fred ahlholmHelen shikRemy luthringerMinerva neurosciencesCompany expects to submitShik communicationsDrug administrationMinerva neurosciences incCompany expectsThird quarterDrug administrationon aprilExecutive chairmanChief executive officerInterest expenseFuture royaltiesRoyalty pharma

vimarsana © 2020. All Rights Reserved.